Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Nice finish with chunk of 0.24s taken out
View:
Post by livermore2 on Sep 07, 2021 4:29pm

Nice finish with chunk of 0.24s taken out

Soon I think we will see a re-rate in this stock.

Good luck to the longs!
Comment by newdaydawning on Sep 07, 2021 7:18pm
A multi-billion dollar valuation is in the cards here once FDA approves TLD-1433 for NMIBC, the anti-viral tackles all Covid variations, ph 1 of GBM and LUNG begin. Assuming 250M shares fully diluted after exercise of 35-cent warrants, the lowest possible price starts at $8.00 per share.
Comment by Pandora on Sep 07, 2021 8:40pm
I believe we have a set of 37.5 cent warrants coming due on November 10, 2021. Will they be exercised or will the price stay down and just let them expire?
Comment by DJDawg on Sep 08, 2021 8:51am
I'm not overly familiar with how warrants work. As shareholders right now, is it a good thing for us for the warrants to expire vs exercised?
Comment by StevenBirch on Sep 08, 2021 9:05am
I would like to see them exercised for 2 reasons - it means the stock would be trading higher and the proceeds that would be going to the company.
Comment by Oden6570 on Sep 08, 2021 9:27am
If you recall TLT mgt extended recent expiring warrants, As Covid is still IMHO effecting Theralase negatively ( trial delays , laser sales ) I would imagine they would do the same for any due in the near future. We have cash for 1 to 1.5 years currently.
Comment by DJDawg on Sep 08, 2021 9:55am
I'm still not clear on warrants. What is the best outcome for the company...expiring warrants or not expiring.
Comment by cashascars on Sep 08, 2021 10:00am
Exerciseing warrants is almost always better than another private placement. IMO cashascars
Comment by CAinPlap on Sep 08, 2021 10:22am
For company management, having the options exercised is the best outcome as it gives them more cash to advance projects. For existing shareholders that do not own warrants, having them expire may be considered the best outcome as their piece of the pie does not get smaller. For warrant holders it shouldn't matter as they can sell the warrants or exercise if in the money.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250